CONNECT WITH US
HealthTech

HealthTech

Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes

Endpoints News logo

Published on

Add as a preferred source on Google
Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes

Eli Lil­ly’s re­ta­tru­tide, the in­cretin shot that has al­ready proven its ef­fec­tive­ness against oth­er as­sets on a cross-tri­al ba­sis, has ce­ment­ed its util­i­ty in a …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Den­mark's Gubra looks be­yond me­tab­o­lism, hopes for first port­fo­lio com­pa­ny this year October 27, 2026

Fer­ring to ac­quire ovary-in-a-dish start­up Ga­me­to for up to $1.38B October 27, 2026

Be­yond the can­cer vac­cine, how did Mer­ck’s on­col­o­gy pipeline do at ES­MO? October 26, 2026

An­throp­ic's lat­est biotech buy is a one-man stealth start­up run by a pseu­do­ny­mous Twit­ter poster

Backed by Amish and Men­non­ites, a new kind of gene ther­a­py com­pa­ny takes shape

Trea­sury's COINS rule draft would nar­row the path for Chi­na biotech deal­mak­ing, ex­perts say



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.